Opinion
Video
Emerging Updates in Front-line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma: Discussion of the CEPHEUS Trial.
Panelists discuss how current treatment approaches for transplant-ineligible newly diagnosed multiple myeloma patients are evolving with the addition of anti-CD38 therapies to standard VRd backbone, while examining unmet needs and the role of MRD negativity as an endpoint through recent trial data including CEPHEUS.
Video content above is prompted by the following:
- To start, please provide a brief overview of treatment regimens for NDMM cases that are TIE or deferred per NCCN guidelines.
- What are current unmet needs in the space?
- How does the addition of an anti-CD38to bortezomib (V)/lenalidomide (R)/dexamethasone (d)impact outcomes in TIE or deferred NDMM?
- What are key takeaways from CEPHEUS (DaraVRd vs VRd)
- What are your thoughts on MRD negativity as a primary endpoint?
Related Videos
Related Content
